Skip to content

Role of Curarization During Anesthesia for Gynecologic Surgical Laparotomy Procedures

The Role of Curarization During Anesthesia for Gynecologic Laparotomy Surgical Procedures: a Double Blind Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03519724
Enrollment
100
Registered
2018-05-09
Start date
2018-07-30
Completion date
2019-01-30
Last updated
2018-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Curarization, Postoperative Residual

Brief summary

The primary outcome of this study is to investigate whether deep NMB reversed with Sugammadex is superior to moderate NMB reversed with Neostigmine, in terms of overall pain in the first 48 hrs after laparoscopic gynecologic surgery, reversal time from NMB (TOF≥0.9) and direct and indirect costs. Additionally we will also assess: drugs consumption for pain and antiemetics (rescue dose), surgical conditions, hemodynamic and respiratory stability, operation time, anesthesia time, total amount and flow rate of CO2, insufflation time, resolution of post-operative ileus, dry mouth and PONV in the first 48 hours, patient satisfaction

Interventions

DRUGSugammadex

Reversal of deep NMB

DRUGNeostigmine

Reversal of moderate NMB

Sponsors

Campus Bio-Medico University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 years BMI between 16 and 40 Kg/m2 ECOG Performance Status tra 0 e 1 American Society Anesthesiologist (ASA) class 1 or 3 Able to provide informed consent to trial procedures

Exclusion criteria

* Age \< 18 or \> 75 years * BMI \<16 o \> 40 Kg/m2 * ECOG Performance Status \>1 * Pregnancy * Active or recent pelvic inflammation * Anticipated airway difficulty * Patients with history of allergy to rocuronium, neostigmine or sugammadex * Allergy to NSAIDs * Previous opioids consumption for chronic pain * Patients receiving drugs for different medical conditions, that may prolong or shorten the duration of rocuronium effect (e.g aminoglycosides, magnesium) * Hepatic or renal failure * Persistent coagulopathy * Neurological or cognitive disorders * Conversion from laparoscopic to open surgery Onset of intraoperative complications

Design outcomes

Primary

MeasureTime frameDescription
Overall pain in the first 48 hrs after gynecologic surgical proceduresFirst 48 hrs after gynecologic surgical procedures0 - 10 NRS scale of the overall pain in the first 48 hrs after gynecologic surgical procedures
Recovery time (or Reversal time) from NMB (TOF≥0.9)The recovery time (or Reversal time) will be measured in minutes after the administration of reversal agent at the end of the surgical procedureThe recovery time (or Reversal time) will be measured in minutes from the administration of reversal agent to a TOF≥0.9

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026